TransCode Therapeutics To Participate at H.C. Wainwright Global Investment Conference
May 20, 2022 09:00 ET
|
TransCode Therapeutics, Inc.
BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be presenting at the H.C. Wainwright Global Investment Conference. The in-person...
TransCode Therapeutics Acquires Option for Radiotheranostic Technology
May 19, 2022 09:00 ET
|
TransCode Therapeutics, Inc.
BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, is pleased to announce its...
TransCode Therapeutics Reports First Quarter 2022 Results; Provides Business Update
May 16, 2022 08:30 ET
|
TransCode Therapeutics, Inc.
BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today reported financial results...
TransCode Therapeutics’ CTO, Dr. Zdravka Medarova, to Moderate 7th Annual RNA Medicine Symposium
April 13, 2022 09:00 ET
|
TransCode Therapeutics, Inc.
BOSTON, April 13, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, is pleased to announce that its...
TransCode Therapeutics Reports 2021 Results; Provides Business Update
March 31, 2022 16:30 ET
|
TransCode Therapeutics, Inc.
BOSTON, March 31, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today reported financial...
TransCode Therapeutics Interview to Air on Bloomberg U.S. on the RedChip Money Report®
March 25, 2022 12:00 ET
|
TransCode Therapeutics, Inc.
BOSTON, March 25, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a biopharmaceutical company committed to defeating cancer using RNA therapeutics, today announced that an...
TransCode Therapeutics Announces Article Published in the Journal Cancers Detailing the Potential for Short RNA-based Drugs in Cancer and a Broad Range of Disorders
March 23, 2022 09:00 ET
|
TransCode Therapeutics, Inc.
BOSTON, March 23, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, in collaboration with teams...
TransCode Therapeutics Announces Expansion of Global RNA Oncology Patent Portfolio
February 14, 2022 09:00 ET
|
TransCode Therapeutics, Inc.
BOSTON, Feb. 14, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today announced that it has...
CORRECTION --TransCode Therapeutics
February 10, 2022 09:46 ET
|
TransCode Therapeutics, Inc.
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- In a release issued under the headline "TransCode Therapeutics to Present at 2020 BIO CEO & INVESTOR CONFERENCE" earlier today by TransCode...
TransCode Therapeutics to Present at 2020 BIO CEO & INVESTOR CONFERENCE
February 10, 2022 08:30 ET
|
TransCode Therapeutics, Inc.
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be presenting at the 2022 BIO CEO & Investor Conference. TransCode’s Chief...